Reuven Schore, MD Oncologist


  • Main Hospital Washington, District of Columbia 20010 1-888-884-2327

Languages Spoken

  • English


Board Certifications

  • American Board of Pediatrics/Hematology-Oncology
  • American Board of Pediatrics

National Provider ID: 1033204227

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

Outside Interests

  • Sigma Tau Pharmaceuticals 
  • Merck, Sharpe & Dohme Corporation 
  • Millenium Pharmaceuticals 



Reuven Schore, MD, is a pediatric oncologist and a member of the Leukemia/Lymphoma Program at Children's National Health System.

Dr. Schore is the vice chair for a Children's Oncology Group study investigating intravenous treatments for patients with high-risk acute lymphoblastic leukemia (ALL).

Education & Training

Education & Training

  • Fellowship Program, Pediatric Hematology/Oncology, 2006
    Cincinnati Children's Hospital Medical Center
  • Residency Program, Pediatrics, 2003
    North Shore University Hospital at Manhasset
  • Internship Program, Pediatrics, 2001
    North Shore University Hospital at Manhasset
  • MD, 2000
    SUNY Health Science Center at Brooklyn
  • BA, 1995
    Brooklyn College of the City University of New York
Patient Stories

Patient Stories: Reuven Schore

Patient story

Andrew's Story

"Our best advice is to take each episode as it comes, and you will get through them all! It may sound like a cliché, but you do learn to live one day at a time and to relish every small milestone in your child's life."



Research & Publications

Research & Publications

Alteration of RhoH expression is associated with human diffuse largeBcell lymphoma

(2005) The 6th International Symposium and Expert Workshops on Leukemia and Lymphoma

Inhibition of the Rho GTPase Rac differentially inhibits proliferation of AML cell lines and may serve as a novel molecular target

(2005) American Society of Hematology Annual Meeting

Inhibition of the Rho GTPase Rac differentially inhibits proliferation of AML cell lines and may serve as a novel molecular target

(2006) 8th Annual OSU Comprehensive Cancer Center Scientific Meeting

Rac a Member of the Rho GTPase Family Is a Potential Target in AML

(2006) Fourth Annual Midwest Blood Club Meeting

Rac Guanosine Triphosphatases represent a potential target in AML

(2008) Leukemia

View publications on PubMed

Isabel's Story

As a pediatric nurse at Children's National, I never imagined that my child would be sick.

Read More of Isabel's Story